AZN•benzinga•
AstraZeneca's Imfinzi-Based Regimen Shows Improved Event-Free Survival In Early-Stage Gastric Cancer Patients
Summary
AstraZeneca's Imfinzi perioperative regimen improved event-free survival in gastric and GEJ cancer. The trial showed a strong trend in overall survival.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 7, 2025 by benzinga